Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00174720
Status:
COMPLETED
Last Update Posted:
2009-04-08
First Post:
2005-09-13
Brief Title:
Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A MultinationalMulticenterRandomizedDouble-BlindPlacebo-ControlledParallel-Group Study to Assess the Efficacy of Ciclesonide Metered-Dose Inhaler at a Daily Dose of 160 μg Administered Either in a Once-Daily in the Morning Regimen 160 μg qd AM for 16 Weeks or in a 160 μg qd AM Regimen for 12 Weeks Preceded by a Twice-Daily Regimen 80 μg Bid for 4 Weeksor in an 80 μg Bid Regimen for 16 Weeksin Adults and Adolescents With Mild to Moderate Persistent Asthma Not Treated With Steroids
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate the efficacy of ciclesonide MDI either as once daily or twice daily in patients with mild to moderate asthma who have not previously been treated with an inhaled corticosteroid
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| XRP1526B3031 | None | None | None |